Squamous cell carcinoma predicts worse prognosis than adenocarcinoma in stage IA lung cancer patients: A population-based propensity score matching analysis

Bo Hao†, Fang Li†, Xiaoxia Wan†, Shize Pan†, Donghang Li†, Congkuan Song†, Ning Li† and Qing Geng†*

1Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, China, 2Department of Ophthalmology, The First Hospital of Wuhan, Wuhan, China, 3Department of Cardiothoracic Surgery, Ezhou Central Hospital, Ezhou, China

Background: Although numerous studies have reported the association between histological types and the prognosis of IA non-small-cell lung cancer (NSCLC) patients, few studies have deeply investigated the impact of pathology on the outcome of NSCLC patients. In this study, we comprehensively explored whether the type of histology influenced the outcome of IA-stage NSCLC patients.

Methods: The study population was obtained from the Surveillance, Epidemiology, and End Results (SEER) program, which is supported by the National Cancer Institute of the United States. To avoid potential bias, the method of propensity score matching (PSM) was used to obtain a balanced cohort for further analysis.

Results: The results from univariate and multivariate regression models showed that lung squamous cell carcinoma (LSQCC) patients were at a significantly greater risk of undergoing shorter overall survival (OS) and lung cancer–specific survival (LCSS). After PSM analysis, LSQCC was still closely associated with a reduction in OS and LCSS. All of these suggested that the histological type was an independent prognostic factor for OS and LCSS.

Conclusion: Our study demonstrated that squamous cell carcinoma predicted worse OS and LCSS in IA-stage NSCLC patients compared with lung adenocarcinoma (LUAD). We suggest that the outcomes of LSQCC and LUAD are very different and that the two histological types should be differently analyzed.

KEYWORDS
lung squamous cell carcinoma, lung adenocarcinoma, histological type, overall survival, lung cancer–specific survival
Introduction

Lung cancer is the leading cause of cancer-related death and thus remains a major public health problem worldwide (1). Non-small-cell lung cancer (NSCLC) accounts for 85% of all cases. Although lung adenocarcinoma (LUAD) has replaced lung squamous cell carcinoma (LSQCC) as the most common case of NSCLC, there is still a large number of patients who are diagnosed with LSQCC (2). A growing number of researchers have come to realize that there are significant differences in prognostic factors and outcomes between LUAD and LSQCC (3–7). Although numerous studies have investigated the relationship between histological types and survival, few studies have comprehensively explored the impact of histological types on survival.

As a result of the difference in the outcomes of adenocarcinoma and squamous cell carcinoma, the Cancer Staging Manuals based on the American Joint Committee on

| TABLE 1 Baseline characteristics before and after matching. | Full cohort | Adenocarcinoma | SCC* | Matched cohort | Adenocarcinoma | P value |
|-----------------------------------------------------------|-------------|---------------|------|----------------|---------------|---------|
| Age <0.001* | 3,064 (44.4%) | 11,078 (54.0%) | 2,948 (45.9%) | 2,997 (46.7%) | 0.386 |
| ≤69 | 3,835 (55.6%) | 9,421 (46.0%) | 3,475 (54.1%) | 3,426 (53.3%) | 0.958 |
| >69 | 3,706 (53.7%) | 8,088 (39.5%) | 3,408 (53.6%) | 3,405 (53.0%) | 0.952 |
| Gender <0.001* | | | | | |
| Male | 3,193 (46.3%) | 12,411 (60.5%) | 3,015 (46.4%) | 3,018 (47.0%) | 0.056 |
| Female | 3,193 (46.3%) | 12,411 (60.5%) | 3,015 (46.4%) | 3,018 (47.0%) | 0.056 |
| Race <0.001* | | | | | |
| Caucasian | 6,192 (89.8%) | 17,508 (85.4%) | 5,808 (91.2%) | 5,810 (90.4%) | 0.001* |
| Others | 707 (10.2%) | 2,991 (14.6%) | 615 (8.8%) | 613 (9.6%) | 0.926 |
| Grade <0.001* | | | | | |
| Well/moderate | 3,786 (54.9%) | 15,304 (74.7%) | 3,747 (60.4%) | 3,754 (60.9%) | 0.001* |
| Poor/UD | 2,843 (41.2%) | 3,709 (18.1%) | 2,434 (36.1%) | 2,375 (35.3%) | 0.013 |
| Unknown | 270 (3.9%) | 1,486 (7.2%) | 242 (3.5%) | 294 (38%) | 0.921 |
| Resected LNs <0.001* | | | | | |
| 0 | 1,095 (15.9%) | 2,873 (14.0%) | 970 (15.1%) | 979 (15.2%) | 0.926 |
| 1–3 | 1,373 (19.9%) | 3,979 (19.4%) | 1,266 (19.7%) | 1,260 (19.6%) | 0.981 |
| ≥4 | 4,078 (59.1%) | 12,655 (61.7%) | 3,894 (60.6%) | 3,906 (60.8%) | 0.921 |
| Unknown | 353 (5.1%) | 992 (4.8%) | 293 (4.7%) | 278 (4.3%) | 0.859 |
| Tumor size (mm) <0.001* | | | | | |
| ≤10 | 755 (10.9%) | 2,924 (14.3%) | 689 (10.7%) | 684 (10.6%) | 0.921 |
| 11–20 | 3,505 (50.8%) | 11,031 (53.8%) | 3,332 (51.9%) | 3,332 (52.2%) | 0.859 |
| 21–30 | 2,639 (38.3%) | 6,544 (31.9%) | 2,402 (37.4%) | 2,384 (37.1%) | 0.981 |
| Surgical procedure <0.001* | | | | | |
| Sublobar resection | 2,037 (29.5%) | 5,549 (27.1%) | 1,819 (28.3%) | 1,848 (28.8%) | 0.981 |
| Lobectomy | 4,862 (70.5%) | 14,950 (72.9%) | 4,694 (71.7%) | 7,575 (71.2%) | 0.981 |
| Location 0.001* | | | | | |
| Upper | 4,314 (62.5%) | 12,617 (61.5%) | 4,125 (64.2%) | 4,169 (64.9%) | 0.859 |
| Middle | 304 (4.4%) | 1,134 (5.5%) | 268 (4.2%) | 268 (4.2%) | 0.859 |
| Lower | 2,244 (32.2%) | 6,530 (31.9%) | 1,995 (31.1%) | 1,950 (30.4%) | 0.859 |
| Others | 57 (0.9%) | 218 (1.1%) | 35 (0.5%) | 36 (0.5%) | 0.981 |
| Laterality <0.001* | | | | | |
| Left | 3,063 (44.4%) | 8,294 (40.5%) | 2,860 (44.5%) | 2,843 (44.3%) | 0.763 |
| Right | 3,836 (55.6%) | 12,205 (59.5%) | 3,563 (55.5%) | 3,580 (55.7%) | 0.763 |

UD, undifferentiated; LN, lymph node; SCC, squamous cell carcinoma; *Difference was statistically significant.
Cancer (AJCC) for esophageal adenocarcinoma and squamous cell carcinoma began to be separated since the 7th edition. A similar scenario was also observed in NSCLC. Studies have shown that the prognosis of LSQCC is better than that of LUAD (3, 4), but other studies have shown that the prognosis of LSQCC is worse (5–7). Therefore, the prognostic role of histological types in NSCLC needs to be further studied.

In this study, subjects were obtained from the Surveillance, Epidemiology, and End Results (SEER) database between 2004 and 2013 to investigate the impact of the histological types on survival in patients with IA-stage NSCLC.

Materials and methods

Data source

The study population in our study is from the SEER project, which is funded by the National Cancer Institute of the United States. The project provides clinical characteristics (such as histology, tumor size, tumor, primary tissue location, TNM stage, etc.), treatment strategies (lobectomy and sublobar resection), and survival time, which facilitate researchers to study the prognostic significance of clinical characteristics. Many high-quality studies have been published using data from the SEER database (8–11).

Inclusion criteria

The selection criteria for this study are as follows: (i) pathologically confirmed primary non-small cell lung cancer, and only squamous cell carcinoma and adenocarcinoma; (ii) tumor size less than 3 cm, and no lymph nodes or distant organ metastasis; (iii) excluding no surgery history or patients who received extended lobectomy, total lobectomy, or extended lobectomy; (iv) excluding patients who received chemotherapy before or after surgery; (v) excluding patients who received radiotherapy treatment before or after surgery; (vi) patients >18 years old; (vii) excluding patients with the tumor located in the main bronchus; and (viii) excluding patients with survival time \( \leq 6 \) months.

Data collection

The study population was obtained from the SEER database between 2004 and 2014. The baseline items in this study included demographic characteristics (age, gender, and race), tumor features (histological type, differentiation grade, tumor size, location, laterality, and TNM stage), and treatment strategies (lobectomy and sublobar resection). Histological type identification: 8140–8147, 8244, 8245, 8250–8255, 8260, 8290, 8310, 8320, 8320, 8323, 8330–8332, 8470, 8480–8481, 8550–8551, and...
8570–8573 were identified as adenocarcinoma, and 8052, 8070–8075, 8078, and 8083–8084 were identified as squamous cell carcinoma (12–14). Surgical procedures (SPs) were divided into sublobar resection (SR) (code: 21, 22) and lobectomy (LT) (code: 30, 33). SR included wedge resection and segmentectomy.

The primary endpoints in our study were overall survival (OS) and lung cancer–specific survival (LCSS). OS was identified as the time from diagnosis to death, and LCSS was defined as the time from diagnosis to death due to lung cancer. Patients who were still alive at the end of the follow-up or who died from other causes were defined as censored patients.

### TABLE 2 Univariate and multivariate regression analyses for overall survival and lung cancer–specific survival before matching.

|                | Overall survival | Lung cancer–specific survival |
|----------------|------------------|------------------------------|
|                | HR^a 95% CI^a    | P^a                          | HR^b 95% CI^b    | P^b                          |
| Age ≤69        | 1                | 1                            | 1                | 1                            |
| >69            | 1.772            | 1.708–1.837                  | <0.001^c         | 1.226                        | 1.148–1.310                  | <0.001^c         |
| Gender Male    | 1                | 1                            | 1                | 1                            |
| Female         | 0.687            | 0.662–0.712                  | <0.001^c         | 0.764                        | 0.715–0.816                  | <0.001^c         |
| Race Caucasian | 1                | 1                            | 1                | 1                            |
| Others         | 0.845            | 0.798–0.893                  | <0.001^c         | 0.957                        | 0.867–1.056                  | 382              |
| Location Upper | 1                |                               | 1                |                              |
| Middle         | 1.022            | 0.943–1.108                  | 0.588            | 0.975                        | 0.839–1.133                  | 0.742            |
| Lower          | 1.031            | 0.992–1.072                  | 0.123            | 0.981                        | 0.913–1.055                  | 0.607            |
| Others         | 1.091            | 0.916–1.300                  | 0.330            | 1.197                        | 0.882–1.625                  | 0.248            |
| Laterality Left| 1                |                               | 1                |                              |
| Right          | 0.970            | 0.935–1.006                  | 0.135            | 1.014                        | 0.948–1.076                  | 0.754            |
| Grade Well/moderate | 1 | 1 | 1 | 1 |
| Poor/UD        | 1.429            | 1.373–1.478                  | <0.001^c         | 1.635                        | 1.522–1.756                  | <0.001^c         |
| Unknown        | 0.847            | 0.993–1.070                  | 0.847            | 0.993                        | 0.922–1.071                  | 0.864            |
| Resected LNs 0 | 1                |                               | 1                |                              |
| 1–3            | 0.665            | 0.629–0.703                  | <0.001^c         | 0.765                        | 0.720–0.812                  | <0.001^c         |
| ≥4             | 0.503            | 0.480–0.528                  | <0.001^c         | 0.616                        | 0.581–0.653                  | <0.001^c         |
| Unknown        | 0.606            | 0.555–0.662                  | <0.001^c         | 0.708                        | 0.646–0.777                  | <0.001^c         |
| Tumor size (mm) ≤10 | 1 | 1 | 1 | 1 |
| 11–2           | 1.065            | 1.006–1.128                  | 0.029^c          | 1.111                        | 1.049–1.178                  | <0.001^c         |
| 21–30          | 1.250            | 1.178–1.326                  | <0.001^c         | 1.320                        | 1.241–1.403                  | <0.001^c         |
| SP SR          | 1                |                               | 1                |                              |
| LR             | 0.615            | 0.592–0.639                  | <0.001^c         | 0.763                        | 0.727–0.880                  | <0.001^c         |
| Histology AD   | 1.670            | 1.608–1.735                  | <0.001^c         | 1.402                        | 1.347–1.459                  | <0.001^c         |

HR, hazard ratio; UD, undifferentiated; LN, lymph node; AD, adenocarcinoma; SCC, squamous cell carcinoma; SR, sublobar resection; LR, lobectomy; SP, surgical procedure.

^aUnivariate analysis.

^bMultivariate analysis.

^cDifference was statistically significant.
Statistical analysis

The Wilcoxon test was performed to calculate the difference in the distributions of continuous data (such as age, number of resected regional lymph nodes, and TS), while the Pearson $\chi^2$ test was used to assess the difference in categorical variables (such as gender, location, laterality, histological type, and differentiation grade). The Kaplan–Meier method was used to establish the curves of OS and LCSS, and the differences were calculated by using a log-rank test. Survival comparisons of all prognostic factors were analyzed by performing univariate Cox regression analysis, and multivariate analysis was performed only when univariate analysis indicated that there was a statistical significance. To balance clinical variables and reduce potential selection bias, propensity score matching (PSM) was used (15, 16). Due to the great heterogeneity of variables, a one-to-one nearest-neighbor matching with the caliper set at 0.001 was used to create a balanced cohort.

All $P$ values in our study were two-sided, and only when $P < 0.05$ was considered to indicate a statistical significance. In univariate and multivariate Cox regression models, the hazard ratios (HRs) and their 95% CIs for survival analyses were calculated using SPSS 22.0 (IBM, Armonk, NY). Propensity score-matched analysis and survival curves were established by R 4.0.1 (R, Vienna, Austria).

Results

Baseline characteristics of the population

After selection, a total of 27,398 patients with T1N0M0 NSCLC (only adenocarcinoma and squamous cell carcinoma) were included (detailed strategies shown in Supplementary Figure S1), of whom 20,499 patients were pathologically confirmed LUAD and 6,899 LSQCC. Among them, 11,794 were male and 15,604 were female. The study population spanned from 1 January 2004 to 31 December 2013. The mean age for the study population was 68.47 (±9.37) years. The median follow-up time for the LUAD patients was 65 months and for LSQCC patients was 57 months. The detailed descriptions of the subgroups of each variable and the correlation between each variable and histology are presented in Table 1. Compared with patients diagnosed with adenocarcinoma, LSQCC patients were more likely to be elderly and male. Additionally, the squamous cell carcinoma seems more likely to be located in the left lung and has a poor tumor differentiation grade compared with LUAD patients. After PSM analyses, 6,423 pairs were created in the adenocarcinoma and squamous cell carcinoma groups. There was no significant difference in any subgroup. In addition, the distributions of the propensity score were balanced between the two groups (Supplementary Figure S2 and Table 1).
Survival analysis before matching

As shown in Figure 1A, survival curves established by Kaplan–Meier revealed that patients who were diagnosed with adenocarcinoma had better OS than those diagnosed with squamous cell carcinoma. The results from univariate [hazard ratio (HR) = 1.670, 95% CI [1.608, 1.735], P < 0.001] and multivariate (HR = 1.402, 95% CI [1.347, 1.459], P < 0.001) regression analyses showed that NSCLC patients with squamous cell carcinoma experienced shorter OS compared with patients with adenocarcinoma (Table 2). As depicted in Figure 1B, LSQCC was associated with poorer LCSS.

### Table 3: Univariate and multivariate regression analyses for overall survival and lung cancer–specific survival after matching.

| Overall survival | Lung cancer–specific survival |
|------------------|------------------------------|
| HR^a | 95% CI^a | P^a | HR^b | 95% CI^b | P^b | HR^a | 95% CI^a | P^a | HR^b | 95% CI^b | P^b |
| Age | | | | | | | | | | | |
| ≤69 | 1 | | | | | | | | | | |
| >69 | 1.561 | 1.481–1.644 | <0.001^c | 1.515 | 1.437–1.597 | <0.001^c | 1.118 | 1.016–1.230 | 0.022^c | 1.119 | 1.016–1.231 | 0.022^c |
| Gender | | | | | | | | | | | |
| Male | 1 | | | | | | | | | | |
| Female | 0.802 | 0.761–0.844 | <0.001^c | 0.780 | 0.741–0.821 | <0.001^c | 0.883 | 0.802–0.971 | 0.010^c | 0.890 | 0.808–0.979 | 0.016^c |
| Race | | | | | | | | | | | |
| Caucasian | 1 | | | | | | | | | | |
| Others | 0.866 | 0.791–0.950 | 0.002^d | 0.892 | 0.813–0.977 | 0.011^d | 1.031 | 0.879–1.209 | 0.705 | 1.031 | 0.879–1.209 | 0.705 |
| Location | | | | | | | | | | | |
| Upper | | | | | | | | | | | |
| Middle | 1.055 | 0.931–1.196 | 0.400 | 1.195 | 0.959–1.490 | 0.113 | 1.195 | 0.959–1.490 | 0.113 | 1.195 | 0.959–1.490 | 0.113 |
| Lower | 1.039 | 0.983–1.099 | 0.177 | 1.004 | 0.904–1.115 | 0.946 | 1.004 | 0.904–1.115 | 0.946 | 1.004 | 0.904–1.115 | 0.946 |
| Others | 0.865 | 0.611–1.225 | 0.413 | 1.040 | 0.574–1.884 | 0.896 | 1.040 | 0.574–1.884 | 0.896 | 1.040 | 0.574–1.884 | 0.896 |
| Laterality | | | | | | | | | | | |
| Left | | | | | | | | | | | |
| Right | 1.010 | 0.960–1.063 | 0.706 | 1.108 | 1.007–1.220 | 0.036^c | 1.118 | 1.015–1.230 | 0.023^c | 1.118 | 1.015–1.230 | 0.023^c |
| Grade | | | | | | | | | | | |
| Well/moderate | | | | | | | | | | | |
| Poor/UD | 1.134 | 1.076–1.195 | <0.001^c | 1.189 | 1.128–1.253 | <0.001^c | 1.390 | 1.261–1.532 | <0.001^c | 1.383 | 1.254–1.525 | <0.001^c |
| Unknown | 1.023 | 0.900–1.162 | 0.730 | 1.081 | 0.951–1.229 | 0.234 | 1.070 | 0.837–1.368 | 0.588 | 1.125 | 0.880–1.440 | 0.348 |
| Resected LNs | | | | | | | | | | | |
| 0 | 1 | | | | | | | | | | |
| 1–3 | 0.680 | 0.628–0.736 | <0.001^c | 0.778 | 0.713–0.849 | <0.001^c | 0.941 | 0.881–1.106 | 0.463 | 0.855 | 0.726–1.007 | 0.060 |
| ≥4 | 0.555 | 0.519–0.593 | <0.001^c | 0.666 | 0.612–0.726 | <0.001^c | 0.829 | 0.722–0.953 | 0.086^d | 0.731 | 0.634–0.842 | <0.001^c |
| Unknown | 0.621 | 0.545–0.707 | <0.001^c | 0.751 | 0.654–0.861 | <0.001^c | 0.823 | 0.638–1.062 | 0.134^d | 0.760 | 0.588–0.982 | 0.036^c |
| Tumor size (mm) | | | | | | | | | | | |
| ≤10 | | | | | | | | | | | |
| 11–20 | 1.041 | 0.954–1.136 | 0.365 | 1.098 | 1.005–1.188 | 0.039^c | 1.280 | 1.063–1.541 | 0.009^c | 1.280 | 1.062–1.543 | 0.009^c |
| 21–30 | 1.139 | 1.042–1.246 | 0.004^d | 1.290 | 1.176–1.415 | <0.001^c | 1.755 | 1.457–2.113 | <0.001^c | 1.775 | 1.469–2.145 | <0.001^c |
| SP | | | | | | | | | | | |
| SR | 1 | | | | | | | | | | |
| LT | 0.644 | 0.610–0.680 | <0.001^c | 0.759 | 0.708–0.813 | <0.001^c | 0.920 | 0.827–1.025 | 0.130 | 0.920 | 0.827–1.025 | 0.130 |
| Pathology | | | | | | | | | | | |
| AD | 1 | | | | | | | | | | |
| SCC | 1.310 | 1.244–1.381 | <0.001^c | 1.339 | 1.271–1.411 | <0.001^c | 1.137 | 1.032–1.252 | 0.009^c | 1.160 | 1.053–1.277 | 0.003^c |

HR, hazard ratio; UD, undifferentiated; LN, lymph node; AD, adenocarcinoma; SCC, squamous cell carcinoma; SR, sublobar resection; LR, lobectomy; SP, surgical procedure.

^aUnivariate analysis.

^bMultivariate analysis.

^cDifference was statistically significant.
compared with LUAD. The results from multivariate regression analysis indicated that histological type was an independent prognostic factor for LCSS, and LSQCC predicted worse LCSS compared with LUAD (HR = 1.301, 95% CI [1.212, 1.397], \(P < 0.001\)). As presented in Table 2, we could also find that older age, male, poorer tumor differentiation, a smaller number of resected lymph nodes, and larger tumor size were associated with worse OS and LCSS, respectively. Moreover, NSCLC patients with IA stage who underwent lobectomy had favorable OS (univariate: HR = 0.615, 95% CI [0.592, 0.639], \(P < 0.001\); multivariate: HR = 0.763, 95% CI [0.727, 0.800], \(P < 0.001\)); however, as for LCSS, univariate analysis showed a significant correlation (HR = 0.860, 95% CI [0.798, 0.926], \(P < 0.001\)), and multivariate analysis showed no significant correlation (HR = 0.934, 95% CI [0.852, 1.023], \(P = 0.141\)).

**Survival analysis after matching**

To reduce potential selection bias, PSM analysis was conducted. In the balanced cohort, the evidence from survival curves suggested that LSQCC predicted worse OS and LCSS compared with LUAD (shown in Figures 2A,B). In the univariate and multivariate Cox regression models, the results showed that LSQCC patients underwent shorter OS (univariate: HR = 1.310, 95% CI [1.244, 1.381], \(P < 0.001\); multivariate: HR = 1.339, 95% CI [1.271, 1.411], \(P < 0.001\)) and LCSS (univariate: HR = 1.137, 95% CI [1.032, 1.252], \(P = 0.009\); multivariate: HR = 1.160, 95% CI [1.053, 1.277], \(P = 0.003\)) compared with LUAD (Table 3). Patients with lobectomy experienced favorable OS but not LCSS compared with those who received sublobar resection. In addition, age, gender, tumor differentiation grade, the number of resected lymph nodes, and tumor size were independent prognostic factors for OS and LCSS, as indicated in multivariate Cox regression analyses (Table 3).

**Subgroup analyses of the population stratified by tumor size**

The prognosis of early-stage NSCLC patients was closely associated with tumor size. Thus, the full cohort was divided into three subgroups according to the tumor size. Because...
multivariate regression analysis was more reliable than univariate analysis, only multivariate analyses were shown. In Table 4, the results show that adenocarcinoma yielded better OS compared with squamous cell carcinoma in different tumor sizes. Similar results were also observed in LCSS (Table 5). Moreover, gender, the number of resected lymph nodes, and tumor differentiation grade were independent prognostic factors for OS and LCSS regardless of the tumor size (Tables 4 and 5).

### Subgroup analyses of the population stratified by surgical procedures

To further investigate the effects of the surgical procedures on OS and LCSS in patients, the full cohort was stratified by surgical procedures. As shown in Tables 6 and 7, no matter what surgical procedures were performed, LSQCC was associated with worse OS and LCSS compared with LUAD. Furthermore, age, gender, tumor differentiation grade, tumor size, and the number of resected lymph nodes were independent prognostic factors for OS and LCSS (Tables 6 and 7).

### Discussion

In this study, we attempted to explore the impact of the histological types on the prognosis of IA NSCLC patients. We found that IA NSCLC patients with squamous cell carcinoma were at a significantly greater risk of lower survival compared with those with adenocarcinoma. After PSM analysis, squamous cell carcinoma was still closely associated with shorter OS and LCSS. To further explore the effect of histology type on OS and LCSS, the full cohort of the study population was stratified by tumor size and surgical procedures for further analysis. Although many studies have been conducted on the relationship between histology and prognosis in patients with IA NSCLC, other variables were mainly explored, and the role of histological types in prognosis was seldom comprehensively analyzed. However, the survival rate of LSQCC is different

| Tumor size ≤ 10 mm | 10 mm < Tumor size ≤ 20 mm | 20 mm < Tumor size ≤ 30 mm |
|-------------------|-----------------------------|---------------------------|
| **HR**            | **95% CI**                  | **P**                     | **HR**            | **95% CI**                  | **P**                     | **HR**            | **95% CI**                  | **P**                     |
| Age ≤69           | 1                           |                            | 1.170             | 1.064–1.286       | 0.001*                    | 1.151             | 1.038–1.276       | 0.008*                    |
| Age >69           | 0.750                       | 0.599–0.938                | 0.012*           | 0.790             | 0.719–0.868                | <0.001*          | 0.879             | 0.792–0.975                | 0.015*                    |
| Gender Male       | 1                           |                            | 1.548             | 1.392–1.722       | <0.001*                    | 1.417             | 1.265–1.588       | <0.001*                    |
| Gender Female     | 0.964                       | 0.860–1.088                | 0.039*           | 1.062             | 1.009–1.117                | 0.017*           | 1.186             | 1.029–1.360                | 0.007*                    |
| Grade Well/moderate | 1                           |                            | 1.548             | 1.392–1.722       | <0.001*                    | 1.417             | 1.265–1.588       | <0.001*                    |
| Grade Poor/UD     | 1.284                       | 1.106–1.482                | 0.032*           | 1.786             | 1.578–2.013                | <0.001*          | 1.760             | 1.557–1.987                | <0.001*                    |
| Resected LNs 0    | 1                           |                            | 0.837             | 0.712–0.958       | 0.009*                    | 0.997             | 0.881–1.121       | 0.309*                    |
| Resected LNs 1–3  | 0.672                       | 0.552–0.814                | 0.002*           | 0.846             | 0.734–0.973                | 0.024*           | 0.798             | 0.692–0.924                | 0.019*                    |
| Resected LNs ≥4   | 0.563                       | 0.482–0.650                | 0.002*           | 0.536             | 0.454–0.637                | <0.001*          | 0.542             | 0.463–0.634                | <0.001*                    |
| Resected LNs Unknown | 0.695                       | 0.591–0.811                | 0.001*           | 0.798             | 0.692–0.915                | <0.001*          | 0.720             | 0.616–0.844                | <0.001*                    |
| Pathology AD      | 1                           |                            | 1.324             | 1.019–1.720       | 0.036*                    | 1.173             | 1.051–1.308       | <0.001*                    |
| Pathology SCC     | 1.096                       | 0.895–1.329                | 0.017*           | 1.173             | 1.051–1.308                | <0.001*          | 1.230             | 1.097–1.379                | <0.001*                    |

HR, hazard ratio; UD, undifferentiated; LN, lymph node; AD, adenocarcinoma SCC, squamous cell carcinoma; SR, sublobar resection; LR, lobectomy; SP, surgical procedure.

*Difference was statistically significant.
Our study was based on a large population. However, some researchers found that there was no significant difference in survival rates between LSQCC and LUAD (5–7). Our study also revealed that older age, male, poor tumor differentiation, a larger number of resected lymph nodes, and larger tumor size were associated with worse OS and LCSS compared with squamous cell carcinoma and as a result, it has a higher probability of invading blood vessels (21). Thus, we speculate that the above-mentioned evidence might account for why LSQCC was associated with worse OS and LCSS.

Recently, some studies pointed out that the adenocarcinoma and squamous cell carcinoma are significantly different in many prognostic factors such as age, tumor location, smoking status, gender, pathological stage, clinical TNM stage, tumor differentiation grade, and survival (5, 6). Our study also revealed that older age, male, poor tumor differentiation, a larger number of resected lymph nodes, and larger tumor size were associated with poor OS and LCSS.

Certainly, our study has some limitations. Recently, great progress has been made in targeted therapies and immunotherapies. These patients who received these therapies may survive for a longer period than those who did not. However, IA-stage NSCLC patients were less likely to receive such treatments; thus, there is little possibility that our study has been substantially affected. Second, as a result of the disease and heart disease compared with non-squamous NSCLC (19, 20). Also, LSQCC is likely to be centrally located, and as a result, it has a higher probability of invading blood vessels (21). Thus, we speculate that the above-mentioned evidence might account for why LSQCC was associated with worse OS and LCSS.

Recently, some studies pointed out that the adenocarcinoma and squamous cell carcinoma are significantly different in many prognostic factors such as age, tumor location, smoking status, gender, pathological stage, clinical TNM stage, tumor differentiation grade, and survival (5, 6). Our study also revealed that older age, male, poor tumor differentiation, a larger number of resected lymph nodes, and larger tumor size were associated with poor OS and LCSS.

Certainly, our study has some limitations. Recently, great progress has been made in targeted therapies and immunotherapies. These patients who received these therapies may survive for a longer period than those who did not. However, IA-stage NSCLC patients were less likely to receive such treatments; thus, there is little possibility that our study has been substantially affected. Second, as a result of the

### TABLE 6 Multivariate regression analyses for overall survival stratified by surgical procedure.

| Sublobar resection | Lobectomy |
|--------------------|-----------|
| **Age**            |           |
| ≤69                | HR 1.000  |
| >69                | HR 1.536  |
| **Gender**         |           |
| Male               | HR 1.000  |
| Female             | HR 0.742  |
| **Grade**          |           |
| Well/moderate      | HR 0.872  |
| Poor/UD            | HR 0.680  |
| Unknown            | HR 0.746  |
| **Resected LNs**   |           |
| 0                  | HR 1.000  |
| 1–3                | HR 0.778  |
| ≥4                 | HR 0.627  |
| Unknown            | HR 0.746  |
| **Tumor size (mm)**|           |
| ≤10                | HR 1.000  |
| 11–20              | HR 1.16   |
| 21–30              | HR 1.374  |
| **Pathology**      |           |
| AD                 | HR 1.353  |
| SCC                | HR 1.263  |

**HR**, hazard ratio; **UD**, undifferentiated; **LN**, lymph node; **AD**, adenocarcinoma; **SCC**, squamous cell carcinoma.

### TABLE 7 Multivariate regression analyses for lung cancer-specific survival stratified by surgical procedures.

| Sublobar resection | Lobectomy |
|--------------------|-----------|
| **Age**            |           |
| ≤69                | HR 1.000  |
| >69                | HR 1.536  |
| **Gender**         |           |
| Male               | HR 1.000  |
| Female             | HR 0.742  |
| **Grade**          |           |
| Well/moderate      | HR 0.872  |
| Poor/UD            | HR 0.680  |
| Unknown            | HR 0.746  |
| **Resected LNs**   |           |
| 0                  | HR 1.000  |
| 1–3                | HR 0.778  |
| ≥4                 | HR 0.627  |
| Unknown            | HR 0.746  |
| **Tumor size (mm)**|           |
| ≤10                | HR 1.000  |
| 11–20              | HR 1.16   |
| 21–30              | HR 1.374  |
| **Pathology**      |           |
| AD                 | HR 1.353  |
| SCC                | HR 1.263  |

**HR**, hazard ratio; **UD**, undifferentiated; **LN**, lymph node; **AD**, adenocarcinoma; **SCC**, squamous cell carcinoma.

**a**Difference was statistically significant.
nature of the retrospective study, some bias was inevitable. Our study performed multivariate Cox regression analyses to remove potential bias as much as possible. Third, information about the R status of patients who received surgery was not provided, which was closely associated with tumor recurrence and outcome. However, the early-stage tumor was most likely to be completely resected, thus achieving R0 status. Finally, we did not have any information on comorbidities, functional status, or pulmonary function of the study population, and we will explore the relationship between these factors and survival in our independent cohort. Moreover, our results need to be further validated in a large randomized cohort study in the future.

Taken together, our study demonstrated that LSQCC predicted worse OS and LCSS in IA-stage NSCLC patients compared with LUAD. The outcomes of LSQCC and LUAD were quite different, and we feel that the two histologic types need to be analyzed differently.

**Data availability statement**

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

**Author contributions**

BH, XW, and FL devised the study design, did the manuscript writing, and gave the final approval. SP, DL, and CS performed data collection and analysis. FL, NL, and QG did the manuscript revision and gave the final approval. All authors contributed to the article and approved the submitted version.

**Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s note**

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**Supplementary material**

The Supplementary Material for this article can be found online at: [https://www.frontiersin.org/articles/10.3389/fsurg.2022.944032/full#supplementary-material](https://www.frontiersin.org/articles/10.3389/fsurg.2022.944032/full#supplementary-material).

**References**

1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA: Cancer J Clin. (2016) 66:115–32. doi: 10.3322/caac.21338

2. Youlden DR, Cramb SM, Baade PD. The international epidemiology of lung cancer: geographical distribution and secular trends. J Thorac Oncol. (2008) 3:819–31. doi: 10.1097/JTO.0b013e31818020eb

3. Wisnivesky JP, Henschke C, McGinn T, Iannuzzi MC. Prognosis of stage II non-small cell lung cancer according to tumor and nodal status at diagnosis. Lung Cancer. (2005) 49:181–6. doi: 10.1016/j.lungcan.2005.02.010

4. Strand TE, Rostad H, Moller B, Norstein J. Survival after resection for primary lung cancer: a population based study of 3211 resected patients. Thorax. (2006) 61:710–5. doi: 10.1136/thx.2005.056481

5. Wang BY, Huang JY, Chen HC, Lin CH, Lin SH, Hung WH, et al. The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients. J Cancer Res Clin Oncol. (2020) 146:43–52. doi: 10.1007/s00432-019-03079-8

6. Nakamura H, Sakai H, Kimura H, Miyazawa T, Marushima H, Saji H. Difference in postsurgical prognostic factors between lung adenocarcinoma and squamous cell carcinoma. Ann Thorac Cardiovasc Surg. (2017) 23:291–7. doi: 10.5761/atcs.oa.17-00020

7. Fukui T, Taniguchi T, Kawaguchi K, Fukumoto K, Nakamura S, Sakao Y, et al. Comparisons of the clinicopathological features and survival outcomes between lung cancer patients with adenocarcinoma and squamous cell carcinoma. Gen Thorac Cardiovasc Surg. (2015) 63:507–13. doi: 10.1007/s11748-015-0564-5

8. Liu Y, Shan L, Shen J, Liu L, Wang J, He J, et al. Choice of surgical procedure—lobectomy, segmentectomy, or wedge resection—for patients with stage T1cN0M0 small cell lung cancer: a population-based study. Thorac Cancer. (2019) 10:593–600. doi: 10.1111/1759-7714.12943

9. Dai C, Shen J, Ren Y, Zhong S, Zheng H, He J, et al. Choice of surgical procedure for patients with non-small-cell lung cancer ≤1 cm or >1 to 2 cm among lobectomy, segmentectomy, and wedge resection: a population-based study. J Clin Oncol. (2016) 34:3175–82. doi: 10.1200/JCO.2015.64.6729

10. Soneji S, Tanner NT, Silvestri GA, Lathan CS, Black W. Racial and ethnic disparities in early-stage lung cancer survival. Chest. (2017) 152:857–97. doi: 10.1016/j.chest.2017.03.009

11. Zhang R, Li P, Li Q, Qiao Y, Xu T, Ruan P, et al. Radiotherapy improves the survival of patients with stage IV NSCLC: a propensity score matched analysis of the SEER database. Cancer Med. (2018) 7:5015–26. doi: 10.1002/cam4.1776

12. Wang Y, Pang Z, Chen X, Bie F, Wang Y, Wang G, et al. Survival nomogram for patients with initially diagnosed metastatic non-small cell lung cancer: a SEER-based study. Future Oncol. (2019) 15:3395–409. doi: 10.2217/fon-2019-0007

13. Morgensztern D, Waqar S, Subramanian J, Gao F, Trinkaus K, Govindan R. Prognostic significance of tumor size in patients with stage III non-small-cell lung cancer.
cancer: a surveillance, epidemiology, and end results (SEER) survey from 1998 to 2003. *J Thorac Oncol*. (2012) 7:1479–84. doi: 10.1097/JTO.0b013e318267d032

14. Zhao M, Lu T, Huang Y, Yin J, Jiang T, Li M, et al. Survival and long-term cause-specific mortality associated with stage IA lung adenocarcinoma after wedge resection vs. segmentectomy: a population-based propensity score matching and competing risk analysis. *Front Oncol*. (2019) 9:593. doi: 10.3389/fonc.2019.00593

15. Winger DG, Nason KS. Propensity score analysis in thoracic surgery: when, why, and an introduction to how. *J Thorac Cardiovasc Surg*. (2016) 151:1484–7. doi: 10.1016/j.jtcvs.2016.02.036

16. McMurry TL, Hu Y, Blackstone EH, Kozower BD. Propensity scores: methods, considerations, and applications in the journal of thoracic and cardiovascular surgery. *J Thorac Cardiovasc Surg*. (2015) 150:14–9. doi: 10.1016/j.jtcvs.2015.03.037

17. Jemal A, Clegg LX, Ward E, Ries LA, Wu X, Jamison PM, et al. Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival. *Cancer*. (2004) 101:3–27. doi: 10.1002/cncr.20288

18. Puri V, Garg N, Engelhardt EE, Kreisel D, Crabtree TD, Meyers BF, et al. Tumor location is not an independent prognostic factor in early stage non-small cell lung cancer. *Ann Thorac Surg*. (2010) 89:1053–9. doi: 10.1016/j.athoracsur.2010.01.020

19. Janssen-Heijnen ML, Schipper RM, Razenberg PP, Crommelin MA, Coebergh JW. Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. *Lung Cancer*. (1998) 21:105–13. doi: 10.1016/S0169-5002(98)00039-7

20. Papi A, Casoni G, Caramori G, Guzzinati I, Boschetto P, Ravenna F, et al. COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinoma. *Thorax*. (2004) 59:679–81. doi: 10.1136/thx.2003.018291

21. Hirsch FR, Spreatico A, Novello S, Wood MD, Simms L, Papotti M. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. *J Thorac Oncol*. (2008) 3:1468–81. doi: 10.1097/JTO.0b013e318189f551